Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors

被引:29
|
作者
Aasen, Synnove Nymark [1 ,2 ]
Parajuli, Himalaya [1 ]
Tuyen Hoang [1 ]
Feng, Zichao [1 ,3 ]
Stokke, Krister [1 ]
Wang, Jiwei [1 ,3 ]
Roy, Kislay [1 ]
Bjerkvig, Rolf [1 ,4 ]
Knappskog, Stian [2 ,5 ]
Thorsen, Frits [1 ,4 ,6 ]
机构
[1] Univ Bergen, Kristian Gerhard Jebsen Brain Tumour Res Ctr, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway
[2] Haukeland Hosp, Dept Oncol & Med Phys, Jonas Lies Vei 65, N-5021 Bergen, Norway
[3] Shandong Univ, Brain Sci Res Inst, 44 Wenhuaxi Rd, Jinan 250100, Shandong, Peoples R China
[4] Luxembourg Inst Hlth, Dept Oncol, NorLux Neurooncol Lab, 84 Val Fleuri, L-1526 Luxembourg, Luxembourg
[5] Univ Bergen, Sect Oncol, Dept Clin Sci, N-5020 Bergen, Norway
[6] Univ Bergen, Dept Biomed, Mol Imaging Ctr, Jonas Lies Vei 91, N-5009 Bergen, Norway
关键词
melanoma; brain metastasis; BRAF; MAPK; PI3K; combined treatment; apoptosis; CANCER CELLS; ACQUIRED-RESISTANCE; BUPARLISIB BKM120; BRAIN METASTASIS; DOSE-ESCALATION; IN-VITRO; MEK; APOPTOSIS; EXPRESSION; SURVIVIN;
D O I
10.3390/ijms20174235
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Malignant melanoma is the most aggressive type of skin cancer and is closely associated with the development of brain metastases. Despite aggressive treatment, the prognosis has traditionally been poor, necessitating improved therapies. In melanoma, the mitogen activated protein kinase and the phosphoinositide 3-kinase signaling pathways are commonly altered, and therapeutically inhibiting one of the pathways often upregulates the other, leading to resistance. Thus, combined treatment targeting both pathways is a promising strategy to overcome this. Here, we studied the in vitro and in vivo effects of the PI3K inhibitor buparlisib and the MEK1/2 inhibitor trametinib, used either as targeted monotherapies or in combination, on patient-derived melanoma brain metastasis cell lines. Scratch wound and trans-well assays were carried out to assess the migratory capacity of the cells upon drug treatment, whereas flow cytometry, apoptosis array and Western blots were used to study apoptosis. Finally, an in vivo treatment experiment was carried out on NOD/SCID mice. We show that combined therapy was more effective than monotherapy. Combined treatment also more effectively increased apoptosis, and inhibited tumor growth in vivo. This suggests a clinical potential of combined treatment to overcome ceased treatment activity which is often seen after monotherapies, and strongly encourages the evaluation of the treatment strategy on melanoma patients with brain metastases.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] HDAC inhibitors restore BRAF inhibitor sensitivity by altering PI3K and survival signaling in melanoma
    Hersey, Peter
    Gallagher, Stuart J.
    CANCER RESEARCH, 2018, 78 (13)
  • [42] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [43] The PI3K Pathway: Background and Treatment Approaches
    Lux, Michael P.
    Fasching, Peter A.
    Schrauder, Michael G.
    Hein, Alexander
    Jud, Sebastian M.
    Rauh, Claudia
    Beckmann, Matthias W.
    BREAST CARE, 2016, 11 (06) : 398 - 404
  • [44] CoA Synthase is in complex with p85αPI3K and affects PI3K signaling pathway
    Breus, Oksana
    Panasyuk, Ganna
    Gout, Ivan T.
    Filonenko, Valeriy
    Nemazanyy, Ivan
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 385 (04) : 581 - 585
  • [45] REDUCED CANCER CELL SENSITIVITY TO TUMOR TREATING FIELDS (TTFIELDS) THROUGH ACTIVATION OF THE PI3K/AKT/MTOR SIGNALING PATHWAY CAN BE MITIGATED USING PI3K INHIBITORS OR PI3K/MTOR DUAL INHIBITORS
    Klein-Goldberg, Anat
    Voloshin, Tali
    Zemer-Tov, Efrat
    Paz, Rom
    Koren, Lilach
    Wainer-Katsir, Kerem
    Volodin, Alexandra
    Koltun, Bella
    Brant, Boris
    Haber, Adi
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    NEURO-ONCOLOGY, 2021, 23 : 84 - 84
  • [46] Association between MAPK and PI3K/Akt signaling pathway-related gene polymorphisms and migraine
    Wang, Mingxue
    Gu, Yujia
    Meng, Shuhan
    Kang, Lixin
    Yang, Jing
    Sun, Degang
    Liu, Yuxing
    Wan, Ze
    Shan, Yi
    Xue, Dongjie
    Su, Chang
    Li, Shufen
    RanYan, Yu
    Liu, Yu
    Pan, Yonghui
    Zhao, Yashuang
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2024, 12 (08):
  • [47] Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma
    Kwong, Lawrence N.
    Davies, Michael A.
    CLINICAL CANCER RESEARCH, 2013, 19 (19) : 5310 - 5319
  • [48] Mutual feedback activation of PI3K and MAPK pathways support combining inhibitors of the two pathways to enhance efficacy
    Zhang, Theresa
    Feldman, Igor
    Paweletz, Cloud
    Nebozhyn, Michael
    Shumway, Stuart Shumway
    Chen, Albert Chen
    Roberts, Brian Roberts
    Arthur, William
    Sathyanarayanan, Sriram
    Lutterbach, Bart
    Strack, Peter
    Huang, Pearl
    Dai, Hongyue
    Loboda, Andrey
    Wafters, James
    CANCER RESEARCH, 2010, 70
  • [49] PI3K and erk MAPK mediate ErbB signaling in Xenopus gastrulation
    Nie, Shuyi
    Chang, Chenbei
    MECHANISMS OF DEVELOPMENT, 2007, 124 (9-10) : 657 - 667
  • [50] PI3K/mTOR AND MAPK PATHWAY UTILIZATION IN BREAST CANCER LINES
    Leung, E.
    Baguley, B. C.
    BREAST, 2013, 22 : S30 - S30